Sol-Gel Technologies (SLGL) Short term Debt (2016 - 2017)
Sol-Gel Technologies (SLGL) reported Short term Debt of $65.3 million for Q4 2017, up 74.99% year-over-year from $37.3 million in Q4 2016, and up 74.99% quarter-over-quarter from $37.3 million in Q4 2016.
Sol-Gel Technologies (SLGL) Short term Debt (2016 - 2017) Analysis & Trends
Sol-Gel Technologies (SLGL) has 2 years of Short term Debt data on file, last reported at $65.3 million in Q4 2017.
- Short term Debt for Q4 2017 came in at $65.3 million, up 74.99% year-over-year; the trailing twelve-month figure through Dec 2017 was $65.3 million (up 74.99% YoY), and the FY2017 annual result was $65.3 million, up 74.99% from the prior year.
- Short term Debt advanced to $65.3 million in Q4 2017 per SLGL's latest filing, from $37.3 million in the prior quarter.
- Over five years, Short term Debt peaked at $65.3 million in Q4 2017 and troughed at $37.3 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 65.34 Mn |
| Dec 31, 2016 | 37.34 Mn |